Uncategorized

HeartFlow’s software models a patient’s coronary arteries from imaging, which cardiologists can use to determine the best course of treatment.

Ken Reali was asked to leave after a deal to buy CartiHeal fell apart, and Bioventus’ share price dropped more than 90% in the past two years. 

Both hospital and payer groups came out in support of the rule finalized Wednesday, finding common ground in the need to streamline prior authorization.

Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.

With experienced technicians retiring faster than their replacements are getting up to speed, the sector faces a potentially costly skills challenge.

Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it has entered into a collaboration agreement with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter “Servier”) for drug discovery research in the field of neurological diseases.

NLRB General Counsel Jennifer Abruzzo issued a memo to all field offices clarifying the board’s recent ruling in a case regarding severance agreements.

Noticias de la actualidad científica y tecnológica del 3 de abril de 2023.     …

Phase III data for Pfizer’s respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.

QurAlis Corporation today announced that the first patient has been dosed in its Phase 1 clinical trial of QRL-201 for the treatment of ALS (ANQUR).